Absci (ABSI) Total Current Liabilities (2020 - 2026)
Absci (ABSI) posted Total Current Liabilities of $20.0 million for Q1 2026, down 12.01% sequentially from $22.8 million in Q4 2025, and down 26.58% YoY from $27.3 million in Q1 2025.
Absci (ABSI) Total Current Liabilities (2020 - 2026) Analysis & Trends
Absci has reported Total Current Liabilities for 7 years, with the latest figure at $20.0 million in Q1 2026.
- Quarterly Total Current Liabilities fell 26.58% year-over-year to $20.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.0 million (down 26.58% YoY) and the FY2025 annual result came in at $22.8 million, down 20.56% from the prior year.
- Total Current Liabilities fell to $20.0 million in Q1 2026 per ABSI's latest filing, from $22.8 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $41.9 million in Q1 2022 and troughed at $20.0 million in Q1 2026.
- A 5-year average of $28.3 million and a median of $28.0 million in 2023 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2023 and 2025: Total Current Liabilities sank 35.05% in 2023, then gained 22.99% in 2025.
- Over 5 years, Total Current Liabilities stood at $30.3 million in 2022, then decreased by 2.35% to $29.6 million in 2023, then declined by 3.05% to $28.7 million in 2024, then dropped by 20.56% to $22.8 million in 2025, then decreased by 12.01% to $20.0 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $20.0 million, $22.8 million, and $29.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Absci | 1.58 Bn | 1.37 Bn | - | 19.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.60 Mn |
| Mar 31, 2026 | 20.03 Mn |
| Dec 31, 2025 | 22.77 Mn |
| Sep 30, 2025 | 29.71 Mn |
| Jun 30, 2025 | 31.32 Mn |
| Mar 31, 2025 | 27.28 Mn |
| Dec 31, 2024 | 28.66 Mn |
| Sep 30, 2024 | 26.69 Mn |
| Jun 30, 2024 | 25.47 Mn |
| Mar 31, 2024 | 25.29 Mn |
| Dec 31, 2023 | 29.56 Mn |
| Sep 30, 2023 | 27.97 Mn |
| Jun 30, 2023 | 25.48 Mn |
| Mar 31, 2023 | 27.20 Mn |
| Dec 31, 2022 | 30.27 Mn |
| Sep 30, 2022 | 30.03 Mn |
| Jun 30, 2022 | 31.69 Mn |
| Mar 31, 2022 | 41.88 Mn |
| Dec 31, 2021 | 33.86 Mn |
| Sep 30, 2021 | 30.25 Mn |